pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)
Shire
Shire is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome, Cytomegalovirus (CMV), Crohn's Dis
JP HQ
3,523 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 3,523
- Programs
- 9
- Drugs
- 8
- Patents
- 0
Recombinant human arylsulfatase A
Phase 2 · mab · Metachromatic Leukodystrophy (MLD)
Recombinant human arylsulfatase A for Metachromatic Leukodystrophy (MLD) is a Phase 2 program (mab) at Shire with 1 ClinicalTrials.gov record(s).
Internal code HGT-MLD-070
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shire
- Phase
- Phase 2
- Modality
- mab
- Indication
- Metachromatic Leukodystrophy (MLD)
- Status
- completed
- Trials
- 1